Skip to main content

Option Care Health Value Stock - Dividend - Research Selection

Bioscrip

ISIN: US68404L2016 , WKN: A2PZEY

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

BioScrip, Inc. provides infusion solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods. The company is primarily involved in the intravenous administration of medications to treat a range of acute and chronic conditions, such as infections, nutritional deficiencies, immunologic and neurologic disorders, cancer, pain, and palliative care. It also offers home nursing products and services to patients suffering from chronic and acute medical conditions. The company offers its services at patient\'s homes, outpatient clinics, nursing facilities, physician\'s offices, and ambulatory infusion centers. It markets and sells its products and services through sales and marketing representatives, and payor relationships. The company was founded in 1993 and is based in Denver, Colorado.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Option Care Health, Inc. (NASDAQ:OPCH) is a favorite amongst institutional investors who own 66%

2025-09-08
Key Insights Significantly high institutional ownership implies Option Care Health's stock price is sensitive to their...

Option Care Health To Participate in Upcoming Investor Conferences

2025-08-25
BANNOCKBURN, Ill., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (“Option Care Health”) (Nasdaq: OPCH), the nation’s largest independent provider of home and alternate site infusion services, will participate in the following upcoming investor conferences: Deutsche Bank Healthcare Summit, being held in New York City, from Wednesday, September 10, 2025 to Thursday, September 11, 2025.Jefferies Healthcare Services Conference, being held in Nashville, on Tuesday, September 30, 2025, in

Bullish Option Care Health Insiders Loaded Up On US$2.54m Of Stock

2025-08-23
Over the last year, a good number of insiders have significantly increased their holdings in Option Care Health, Inc...

Sector Update: Health Care Stocks Advance Late Afternoon

2025-08-22
Health care stocks rose late Friday afternoon, with the NYSE Health Care Index adding 1% and the Hea

Option Care Health taps new CFO

2025-08-21
Meenal Sethna will replace Michael Shapiro as the infusion therapy provider’s chief financial executive in October.

Avis Budget Group, Option Care Health, C3.ai, The RealReal, and DoorDash Shares Plummet, What You Need To Know

2025-08-20
A number of stocks fell in the afternoon session after the major indices continued to pull back, with technology stocks accounting for most of the market's largest decliners. A key reason for this trend is that much of the recent market gains were concentrated in the "AI trade," which includes these large technology and semiconductor companies. So this could also mean that some investors are locking in some gains ahead of more definitive feedback from the Fed.

Option Care Health Announces Chief Financial Officer Transition

2025-08-20
Mike Shapiro to Step Down After 10 Years With the Company; Meenal Sethna Named EVP and CFO Effective October 1, 2025BANNOCKBURN, Ill., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (the “Company” or “Option Care Health”) (Nasdaq: OPCH), the nation’s largest independent provider of home and alternate site infusion services, announced the appointment of Meenal Sethna as Executive Vice President and Chief Financial Officer, effective October 1, 2025. Sethna will succeed Mike Shapiro, w

Senior Health, Home Health & Hospice Stocks Q2 Highlights: Option Care Health (NASDAQ:OPCH)

2025-08-15
Looking back on senior health, home health & hospice stocks’ Q2 earnings, we examine this quarter’s best and worst performers, including Option Care Health (NASDAQ:OPCH) and its peers.

Option Care Health’s Q2 Earnings Call: Our Top 5 Analyst Questions

2025-08-12
Option Care Health’s second quarter was marked by robust top-line growth, but the market reacted negatively to the results. Management credited the double-digit revenue increase to strong execution in both acute and chronic therapy portfolios, as well as deeper partnerships with payers and pharmaceutical manufacturers. CEO John Rademacher noted, “Our national scale and nimble operating model enabled us to deliver consistent results despite industry headwinds.” Gross profit dollar growth was supp

OPCH Q2 Deep Dive: Portfolio Expansion Drives Growth Amid Margin Pressures

2025-08-12
Alternate site health provider Option Care Health (NASDAQ:OPCH) reported Q2 CY2025 results exceeding the market’s revenue expectations, with sales up 15.4% year on year to $1.42 billion. The company expects the full year’s revenue to be around $5.58 billion, close to analysts’ estimates. Its non-GAAP profit of $0.41 per share was 3.6% above analysts’ consensus estimates.